For research use only. Not for therapeutic Use.
Lascufloxacin（Cat No.:I007620）, referred to by various names including KRP-AM-1977, KRP-AM-1977X, KRP-AM-1977Y, KRPAM-1977X, KRPAM-1977Y, and KRPAM-1977, is a novel antibacterial drug candidate. It belongs to the fluoroquinolone class of antibiotics and demonstrates promising potential in combating bacterial infections. Lascufloxacin exhibits a broad spectrum of activity against various bacterial strains, making it suitable for the treatment of different types of infections. As a novel drug candidate, further research and development are ongoing to determine its efficacy, safety, and potential role in clinical practice.
| Catalog Number | I007620 |
| CAS Number | 848416-07-9 |
| Synonyms | KRP-AM1977; KRP-AM-1977; KRP-AM 1977; KRP-AM1977X; KRP-AM1977Y; Lascufloxacin;7-{(3S,4S)-3-[(cyclopropylamino)methyl]-4-fluoropyrrolidin- 1-yl}-6-fluoro-1-(2-fluoroethyl)-8-methoxy-4-oxo- 1,4-dihydroquinoline-3-carboxylic acid |
| Molecular Formula | C21H24F3N3O4 |
| Purity | ≥95% |
| Target | Beta-lactamase |
| Solubility | Soluble in DMSO, not in water |
| Storage | 0 - 4°C for short term , or -20°C for long term. |
| IUPAC Name | 7-[(3S,4S)-3-[(cyclopropylamino)methyl]-4-fluoropyrrolidin-1-yl]-6-fluoro-1-(2-fluoroethyl)-8-methoxy-4-oxoquinoline-3-carboxylic acid |
| InChI | InChI=1S/C21H24F3N3O4/c1-31-20-17-13(19(28)14(21(29)30)9-26(17)5-4-22)6-15(23)18(20)27-8-11(16(24)10-27)7-25-12-2-3-12/h6,9,11-12,16,25H,2-5,7-8,10H2,1H3,(H,29,30)/t11-,16+/m0/s1 |
| InChIKey | ZFIOCUITTUUVPV-MEDUHNTESA-N |
| SMILES | COC1=C2C(=CC(=C1N3CC(C(C3)F)CNC4CC4)F)C(=O)C(=CN2CCF)C(=O)O |
| Reference | 1:Antimicrob Agents Chemother. 2017 Mar 20. pii: AAC.00120-17. doi: 10.1128/AAC.00120-17. [Epub ahead of print] In vitro activities and spectrum of the novel fluoroquinolone, lascufloxacin (KRP-AM1977).Kishii R,Yamaguchi Y,Takei M, PMID: 28320717 DOI: 10.1128/AAC.00120-17 </br><span>Abstract:</span> Lascufloxacin showed a broad spectrum of activity against various clinical isolates. Especially, lascufloxacin showed the most potent activity against gram-positive bacteria among the quinolones tested. Furthermore, lascufloxacin showed incomplete cross-resistance against existing quinolone-resistant strains. Enzymatic analysis indicated that lascufloxacin showed potent inhibitory activity against both wild-type and mutated target enzymes. These results suggested that lascufloxacin may be useful in treating infections caused by various pathogens, including quinolone-resistant strains.Copyright © 2017 American Society for Microbiology. |
